Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BECOME: Biomarkers for ICI Adverse Events in Lung Cancer
NCT05055908Phase 3Recruiting
- Sponsor
- Hunan Cancer Hospital
- Start
- Oct 2021
- Primary completion
- Jul 2025
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of pembrolizumab, atezolizumab in lung cancer, sponsored by Hunan Cancer Hospital. Started Oct 2021; status: recruiting.
02
Drugs
pembrolizumabatezolizumab
03
Conditions
lung cancer
Beyond the preview
Go deeper on NCT05055908.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05055908.